An Open-Label, Investigator-Blinded, Randomized, Parellel Group Study to Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA 325 Versus Enteric-Coated Aspirin.
Phase of Trial: Phase I
Latest Information Update: 07 May 2010
At a glance
- Drugs Aspirin; Aspirin/omeprazole
- Indications NSAID-induced gastrointestinal damage
- Focus Adverse reactions
- Sponsors POZEN
- 07 May 2010 Results were presented at the 29th Annual Scientific Meeting of the American Pain Society (APS), according to a POZEN media release.
- 09 Apr 2007 New trial record.